Literature DB >> 27518480

Survival of acral lentiginous melanoma in the National Cancer Institute of Colombia.

C A Duarte1, J P Flórez1, H G López1, M X Meneses2, E de Vries3.   

Abstract

OBJECTIVE: To determine survival of a cohort of patients with acral lentiginous melanoma (ALM), treated at the National Cancer Institute of Colombia, the largest referral hospital of the country.
METHODS: All patients diagnosed with an invasive ALM between 2003 and 2009 at the Colombian National Cancer Institute were included for analyses and followed for vital status and date of death. Using Kaplan-Meier methods, overall survival at 1, 3 and 5 years post diagnosis was determined, and Cox proportional hazards models were constructed for the variables showing a significant effect on survival in univariate analyses.
RESULTS: Overall survival of this cohort of 90 patients was 77% at 1 year, 59% at 3 years and 54% at 5 years after diagnosis. Females had a better prognosis in univariate analyses but this advantage disappeared in multivariate models. Clinical stage was a strong predictor of survival, in univariate and multivariate models, particularly among elderly patients.
CONCLUSIONS: Prognosis of ALM in Colombia is relatively poor, particularly for patients with higher clinical stage. The large proportions of ALM diagnosed in stage III and IV explain the relatively poor survival, and illustrate the importance of improving prognosis by lowering stage at diagnosis through better education and early detection programmes.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2016        PMID: 27518480     DOI: 10.1111/jdv.13913

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  Spatial clusters and temporal trends of malignant melanoma mortality in Ecuador.

Authors:  Solange Núñez-González; Estefania Bedoya; Daniel Simancas-Racines; Christopher Gault
Journal:  SAGE Open Med       Date:  2020-05-04

2.  Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.

Authors:  Yasuhiro Fujisawa; Shusuke Yoshikawa; Akane Minagawa; Tatsuya Takenouchi; Kenji Yokota; Hiroshi Uchi; Naoki Noma; Yasuhiro Nakamura; Jun Asai; Junji Kato; Susumu Fujiwara; Satoshi Fukushima; Jiro Uehara; Toshihiko Hoashi; Tatsuya Kaji; Taku Fujimura; Kenjiro Namikawa; Manabu Yoshioka; Naoki Murao; Dai Ogata; Kanako Matsuyama; Naohito Hatta; Yoshitsugu Shibayama; Toshiharu Fujiyama; Masashi Ishikawa; Daisuke Yamada; Akiko Kishi; Yoshiyuki Nakamura; Takatoshi Shimiauchi; Kazuyasu Fujii; Manabu Fujimoto; Hironobu Ihn; Norito Katoh
Journal:  Cancer Med       Date:  2019-04-01       Impact factor: 4.452

3.  The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma.

Authors:  Xiaoting Wei; Di Wu; Hang Li; Rui Zhang; Yu Chen; Hong Yao; Zhihong Chi; Xinan Sheng; Chuanliang Cui; Xue Bai; Zhonghui Qi; Ke Li; Shijie Lan; Lizhu Chen; Rui Guo; Xinyu Yao; Lili Mao; Bin Lian; Yan Kong; Jie Dai; Bixia Tang; Xieqiao Yan; Xuan Wang; Siming Li; Li Zhou; Charles M Balch; Lu Si; Jun Guo
Journal:  Ann Surg Oncol       Date:  2020-04-06       Impact factor: 5.344

4.  Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis.

Authors:  Avani M Kolla; Gerardo A Vitiello; Erica B Friedman; James Sun; Aishwarya Potdar; Hala Daou; Norma E Farrow; Clara R Farley; John T Vetto; Dale Han; Marvi Tariq; Georgia M Beasley; Carlo M Contreras; Michael Lowe; Jonathan S Zager; Iman Osman; Russell S Berman; Tracey N Liebman; Jennifer A Stein; Ann Y Lee
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

5.  Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma.

Authors:  Kenjiro Namikawa; Yoshio Kiyohara; Tatsuya Takenouchi; Hisashi Uhara; Hiroshi Uchi; Shusuke Yoshikawa; Sumiko Takatsuka; Hiroshi Koga; Naoko Wada; Hironobu Minami; Masahiro Hatsumichi; Yoshinobu Namba; Naoya Yamazaki
Journal:  J Dermatol       Date:  2020-08-18       Impact factor: 4.005

6.  Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma.

Authors:  Laura Susok; Thilo Gambichler
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-15       Impact factor: 4.553

7.  Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.

Authors:  Xiaoting Wei; Di Wu; Yu Chen; Hang Li; Rui Zhang; Hong Yao; Zhihong Chi; Chuanliang Cui; Xue Bai; Lili Mao; Zhonghui Qi; Ke Li; Shijie Lan; Lizhu Chen; Rui Guo; Xinyu Yao; Bin Lian; Yan Kong; Jie Dai; Bixia Tang; Xuan Wang; Jun Guo; Lu Si
Journal:  Br J Dermatol       Date:  2022-03-25       Impact factor: 11.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.